Relapsing Remitting Multiple Sclerosis News and Research

RSS
Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

BG-12 effective for relapsing–remitting multiple sclerosis

BG-12 effective for relapsing–remitting multiple sclerosis

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Long-term interferon beta benefits unclear in MS

Long-term interferon beta benefits unclear in MS

Interferon beta not associated with less progression of disability in patients with RRMS

Interferon beta not associated with less progression of disability in patients with RRMS

Patients with early-stage MS show sodium accumulation in specific brain regions

Patients with early-stage MS show sodium accumulation in specific brain regions

Fingolimod offers minor added benefit for patients with RRMS

Fingolimod offers minor added benefit for patients with RRMS

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Positive top-line results from Teva’s GALA Phase III trial on RRMS

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Computer-assisted cognitive rehabilitation benefits patients with relapsing-remitting MS

Computer-assisted cognitive rehabilitation benefits patients with relapsing-remitting MS

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

Health Alliance, Bayer sign outcomes-based contract to support MS patients

Health Alliance, Bayer sign outcomes-based contract to support MS patients

Study reveals mechanism of action of laquinimod in patients with RRMS

Study reveals mechanism of action of laquinimod in patients with RRMS

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints